Govindarajan Ameish, Castro Daniela V, Zengin Zeynep B, Salgia Sabrina K, Patel Jalen, Pal Sumanta K
City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Cancers (Basel). 2022 Apr 19;14(9):2049. doi: 10.3390/cancers14092049.
Over the last decade, the treatment paradigm of metastatic renal cell carcinoma has rapidly evolved, with notable changes in the front-line setting. Combination therapies involving the use of either doublet therapy with immune checkpoint inhibitors or combination VEGFR-directed therapies with immune checkpoint inhibitors have significantly improved clinical outcomes, including prolonged overall survival and durable response to treatment. We aim to highlight the Food and Drug Administration-approved front-line therapy options, the navigation of treatment selection, and the future directions of metastatic renal cell carcinoma therapies.
在过去十年中，转移性肾细胞癌的治疗模式迅速演变，一线治疗领域发生了显著变化。涉及使用免疫检查点抑制剂的双联疗法或联合VEGFR靶向疗法与免疫检查点抑制剂的联合疗法显著改善了临床结局，包括延长总生存期和持久的治疗反应。我们旨在强调美国食品药品监督管理局批准的一线治疗方案、治疗选择的指导以及转移性肾细胞癌治疗的未来方向。
